Cancer Health

This week, the Food and Drug Administration (FDA) approved a new blood test to screen for colon cancer, according to an FDA announcement. Guardant Health’s Shield is not a replacement for colonoscopies but has potential to improve the low screening rates for colon cancer, the second leading cause of cancer-related death in the United States (lung cancer tops that list by far).

FDA Approves Blood Test for Colon Cancer

Patients with locally advanced muscle-invasive bladder cancer may benefit from dose-dense gemcitabine and cisplatin. The treatment of preoperative dose-dense gemcitabine and cisplatin chemotherapies was well-tolerated and effective in patients with locally advanced muscle-invasive bladder cancer; however, more research is needed, an expert told CURE®. “The dose-dense part means to...

Dose-Dense Chemo for Muscle-Invasive Bladder Cancer May Be Feasible

The Food and Drug Administration (FDA) on Aug. 6 approved VORANIGO, the first targeted therapy for Grade 2 Isocitrate dehydrogenase (IDH) mutant glioma, a type of brain tumor. Available to patients as a once-daily pill, VORANIGO is the first significant treatment breakthrough in nearly 25 years for Grade 2 IDH mutant glioma, the drug’s maker Servier explained.

FDA approves Servier’s VORANIGO for certain brain tumors

Incorporating information from common blood tests can enhance cancer risk assessment in patients with abdominal symptoms, according to a study publishing July 30th in the open-access journal PLOS Medicine by Meena Rafiq from University College London, UK, and colleagues. Early cancer detection is key to successful treatment. However, many undiagnosed...

Routine blood test results can improve cancer risk assessment in patients with abdominal symptoms

Researchers compared health-related quality of life among patients ages 60 and older with acute myeloid leukemia undergoing different chemotherapy regimens. Lower-intensity treatment with decitabine chemotherapy may be preferable over the current standard of intensive chemotherapy among fit older patients with acute myeloid leukemia (AML), researchers have found. Research published in...

Less-Intense Chemotherapy May Be Preferrable in Older Patients with AML

Patients with NSCLC taking five or more medications tended to have worse survival, highlighting the need for medication management, research showed. Older patients with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy treatment tended to have worse survival outcomes if they were taking five or more other oral or inhaled medications, according to a study published in the Journal of Geriatric Oncology.

Polypharmacy May Shorten Survival in Lung Cancer

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

Cooking With Maryann

This recipe is sooo tasty! It truly is for garlic lovers! It involves sautéing onions and mushrooms in butter and oil until golden, then adding wine to reduce. Garlic, thyme, and parsley are stirred in for flavor, followed by seasoning with salt and pepper. The dish is garnished with additional parsley and served warm, making for a savory, aromatic side. Here's what you'll need to make it:

Garlic Mushrooms in Brown Butter Herb Sauce

Livdelz is an oral therapy to treat patients with primary biliary cholangitis, a progressive autoimmune disease. It is expected to be available in pharmacies next week. The FDA has granted accelerated approval for Livdelzi (seladelpar) to treat patients with primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). PBC is a progressive autoimmune disease that results from the destruction of the bile ducts in the liver. This leads to inflammation, scarring and cirrhosis. The disease affects mostly women.

FDA Grants Accelerated Approval for Rare Liver Disease Drug

SON-080, a novel drug, may reduce chemotherapy-induced peripheral neuropathy in patients previously treated with chemotherapy. The novel drug SON-080 showed promise in the phase 1b portion of the SB211 trial (NCT05435742) focusing on persistent chemotherapy-induced peripheral neuropathy (CIPN) in patients previously treated with chemotherapy, according to a press release from Sonnet BioTherapeutics.1.

Novel Drug SON-080 May Reduce Peripheral Neuropathy From Chemotherapy

A phase 1b study will investigate PTM-01, a directed administration of paclitaxel, in patients with nonmetastatic pancreatic cancer. The FDA has granted clearance to the investigational new drug (IND) application of PTM-01. A phase 1b study of PTM-01 in pancreatic ductal adenocarcinoma (PDAC) will proceed. PTM-01 is a proprietary flexible...

FDA Clears IND Application of Novel Paclitaxel Administration in Pancreatic Cancer

Enrollment will soon begin for the dose-expansion portion of the ongoing phase 1 trial assessing EO-3021 in CLDN18.2-positive tumors. Treatment with EO-3021 (SYSA1801) produced promising preliminary data in a small cohort of patients with advanced, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) cancers expressing Claudin 18.2 (CLDN18.2), according to dose-escalation findings from a phase 1 trial (NCT05980416).1.

EO-3021 Elicits Responses in Advanced CLDN18.2+ Gastric/GEJ Cancer

Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma. The antibody-drug conjugate (ADC), sacituzumab govitecan (Trodelvy), given in the neoadjuvant and adjuvant settings, displayed promising preliminary activity in patients undergoing craniotomy for breast cancer with brain metastases or those with recurrent glioblastoma (GBM), according to a phase 0 window-of-opportunity study (NCT03995706) published in Nature Communications.

Sacituzumab Govitecan Shows Preliminary Activity in Patients With Brain Mets, GBM

Thyroid lymphoma is an extremely rare but highly treatable cancer that affects the thyroid gland. It can cause a mass in the neck, difficulty swallowing, and shortness of breath. Most cases of thyroid cancer start when thyroid gland cells become cancerous. Thyroid lymphoma, meanwhile, is a disease that happens when...

What to Know About Thyroid Lymphoma

Reuters

(Reuters) - The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.

US FDA approves AstraZeneca's non-small cell lung cancer treatment

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy. The FDA has granted priority review to the supplemental biologics license application (sBLA) seeking the approval of durvalumab (Imfinzi) for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy.1.

FDA Grants Priority Review to Durvalumab for LS-SCLC After Concurrent Chemoradiotherapy

The following is a summary of “Patients With Inflammatory Bowel Disease Are at Increased Risk of Hospitalization Due to Respiratory Syncytial Virus,” published in the August 2024 issue of Gastroenterology by Smith et al. Patients with inflammatory bowel disease (IBD) are at high risk of respiratory infections, including...

Increased Risk of Hospitalization in Patients with IBD Following RSV Infection

Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients. Population-based cohort study results were mixed for patients with comorbid chronic kidney disease (CKD) and relapsed/refractory multiple myeloma (RRMM) who received pomalidomide-based treatment...

Challenges With Pomalidomide for Patients With Comorbid RRMM, CKD

Florida State

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Jacksonville Today

Republican Donald Trump has a 7-point lead over Democrat Kamala Harris among Florida voters, 49% to 42%, according to a new poll from the University of North Florida. Four percent are backing another candidate, and 6% are undecided or didn’t answer.

New Florida poll: Trump leads; support strong for abortion and recreational weed

UGN-102 has the potential to be the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer, UroGen says. UroGen has completed its New Drug Application (NDA) submission for UGN-102 (mitomycin) for intravesical solution, suggesting that it has the potential to become the first FDA-approved treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The NDA submission is supported by results from the Phase III ENVISION trial, which demonstrated that patients treated with UGN-102 had a 79.6% complete response (CR) rate at three months following the first instillation.1.

UroGen Pharma Submits FDA New Drug Application for UGN-102, a Potential Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Longeveron’s experimental cell therapy Lomecel-B for mild Alzheimer’s disease. The designation is designed to accelerate the development and review processes for regenerative medicine candidates, including cell therapies, intended to treat, modify, reverse,...

Lomecel-B granted FDA RMAT status for mild Alzheimer’s

NewsBreak

FDA Approves Presurgical, Postsurgical Imfinzi in Some With NSCLC

Imfinzi has been approved as a presurgical treatment with platinum-based chemotherapy and postsurgical treatment alone in surgically removable NSCLC. The Food and Drug Administration (FDA) has...

FDA Approves Presurgical, Postsurgical Imfinzi in Some With NSCLC

Comments / 0